シャーガス病の世界市場：2024年～2031年

概要

世界のシャーガス病市場は、2023年に2億6,800万米ドルに達し、2031年には4億6,700万米ドルに達すると予測され、予測期間2024-2031年のCAGRは7.2%で成長する見込みです。

シャーガス病はアメリカトリパノソーマ症とも呼ばれ、原虫であるトリパノソーマ・クルージによって引き起こされる寄生性の全身性慢性疾患です。シャーガス病は主に吸血性のトリパノソーマによってヒトに感染します。

1つは急性期で、発熱、リンパ腺の腫れ、頭痛、ロマーナ徴候として知られるまぶたの皮膚病変や紫色の腫れなどが見られます。この段階は通常約4～8週間続きます。第二は慢性期で、ほとんどの感染者は何の症状もなく慢性期に入る。しかし、感染者の20～30％は、心臓肥大、心不全、心リズムの変化、心停止などの心疾患や、食道や大腸の肥大などの消化器合併症を発症します。

市場力学：

促進要因

シャーガス病の有病率の上昇

世界のシャーガス病市場の需要は、複数の要因によって牽引されています。主な要因の1つは、世界のシャーガス病有病率の上昇です。世界保健機関（WHO）によると、2023年4月には、シャーガス病の原因となる寄生虫であるトリパノソーマ・クルジに感染している人が世界で600万～700万人いると推定され、毎年約1万2,000人が死亡し、約7,500万人が感染のリスクにさらされています。

年間罹患者数は3～4万人だが、多くの国では発見率が低く（10％未満、多くの場合1％未満）、この病気に罹患している人々は、診断や適切なヘルスケアを受ける上で大きな障壁に遭遇することが多いです。

さらに、啓発プログラム、革新的なプロジェクトの立ち上げ、シャーガス病治療開発のための進行中の研究開発などの政府戦略が、この市場の成長を促進すると思われます。例えば、2023年4月、WHOは、シャーガス病に対する人々の認識を高めることに焦点を当て、一次医療レベルで、重要なケアへのアクセスを提供し、疾病サーベイランスを実施することに焦点を当てています。

また、2022年8月、CUIDAシャーガス・プロジェクトは、シャーガス病の認知度を高め、その活動を促進することを目的としたデジタル・プラットフォームを立ち上げました。

同様に、2022年12月には、チューレーン大学の研究者が、この熱帯病の長期的な合併症である、持続的な心臓障害を予防する新しいシャーガス病ワクチンの開発に取り組んでいます。

阻害要因

高額な治療費、病気に対する認識と診断の欠如、地方における薬へのアクセスの欠如、限られた治療オプション、承認された薬剤の数の少なさ、医療従事者の不足などの要因が市場の妨げになると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • シャーガス病の有病率の上昇
    • 政府の取り組みとシャーガス病に対する意識の高まり
    • 新薬の研究開発資金の確保
  • 抑制要因
    • 治療費の高騰
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• DMIの見解

第6章 タイプ別

• 急性シャーガス病
• 慢性シャーガス病

第7章 薬剤別

• ベンズニダゾール
• ニフルチモックス
• その他

第8章 投与経路別

• 経口
• 非経口

第9章 流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • ロシア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• Bayer AG
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Novartis AG
• Laboratorio Elea Phoenix
• Maprimed
• Nortec Quimica SA
• Upsher-Smith Laboratories, Inc
• Merck and Co
• ChemFish Tokyo Co., Ltd
• Anant Pharmaceuticals Pvt. Ltd
• InBios International Inc

第13章 付録

Overview

The global Chagas disease market reached US$ 268 million in 2023 and is expected to reach US$ 467 million by 2031, growing with a CAGR of 7.2% during the forecast period 2024-2031.

Chagas disease also called American trypanosomiasis, is a parasitic, systemic, and chronic disease caused by the protozoan Trypanosoma cruzi. It is primarily transmitted to humans by blood-sucking triatomine bugs, often called "kissing bugs"

This disease has two types one is the acute phase, symptoms may include fever, swollen lymph glands, headache, and a skin lesion or purplish swelling on the eyelid known as Romana's sign. This phase usually lasts for about 4-8 weeks. The second one is the chronic phase, most infected people enter the chronic phase without any symptoms. However, 20-30% of infected individuals develop cardiac disorders, such as an enlarged heart, heart failure, altered heart rhythm, and cardiac arrest, or digestive complications, such as an enlarged esophagus or colon.

Market Dynamics: Drivers

Rising Prevalence of Chagas Disease

The demand for the global Chagas disease market is driven by multiple factors. One of the primary factors is the rising prevalence of Chagas disease globally. According to the World Health Organization (WHO), in April 2023, an estimated 6-7 million people worldwide are infected with Trypanosoma cruzi, the parasite that causes Chagas disease, leading to some 12,000 deaths every year and leaving some 75 million people at risk of infection.

Annual incidence is 30-40,000 cases, but in many countries, detection rates are low (less than 10% and often less than 1%) and people suffering from the disease often encounter significant barriers to diagnosis and adequate healthcare.

Moreover, government strategies such as awareness programs, innovative project launches, and ongoing research studies in the development of treatment for Chagas disease would drive this market growth. For instance, in April 2023, WHO aimed to focus on the awareness of the Chagas disease among people this year the focus is on increasing awareness of Chagas disease, and by providing access to crucial care and implementing disease surveillance, at the primary health care level.

Also, in August 2022, the CUIDA Chagas project launched its digital platforms aiming at increasing the visibility of Chagas disease and promoting its activities.

Similarly, in December 2022, Tulane University researchers are working on a new Chagas disease vaccine that prevents lasting heart damage, a long-term complication of the tropical disease.

Restraints

Factors such as the high cost of the treatment, lack of awareness & diagnosis of disease, lack of accessibility to medication in rural areas, limited treatment options, a small number of drug approvals, and shortage of health care professional are expected to hamper the market.

Segment Analysis

The global Chagas disease market is segmented based on type, drugs, route of administration, distribution channel, and region.

The benznidazole segment accounted for approximately 45.3% of the global Chagas disease market share

The benznidazole segment is expected to hold the largest market share over the forecast period. Benznidazole is the first drug ever approved by the U.S. FDA to treat Chagas disease, a dangerous parasitic disease that affects an estimated 6 to 8 million people worldwide. It is a nitroimidazole derivative that has been used for the treatment of Chagas disease for several decades.

Benznidazole works by inhibiting the replication of Trypanosoma cruzi, the parasite that causes Chagas disease. The drug is effective in treating early-stage Chagas disease, but it is less effective in treating advanced cases of the disease.

Moreover, the rising number of clinical trials and combination therapy helps to drive this segment's growth in the market. For instance, in April 2023, Novartis Pharmaceuticals announced a study of phase 4 clinical trials for Enalapril and Sacubitril/valsartan. Additionally, the study aims to determine if sacubitril/valsartan leads to a more pronounced reduction in the levels of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) compared to baseline, specifically at the 12-week mark, in individuals with HF characterized by reduced ejection fraction (HFrEF) originating from chronic Chagas cardiomyopathy (CCC).

According to the Frontiers research publication in July 2022, stated that drug repurposing and combination therapy have been proposed as cost-effective strategies to improve Chagas disease treatment. The Miltefosine and Benznidazole combination improves anti-Trypanosoma cruzi in vitro and in vivo efficacy.

Geographical Analysis

North America accounted for approximately 41.2% of the global Chagas disease market share

North America region is expected to hold the largest market share over the forecast period. Chagas disease, also known as American trypanosomiasis, is a potentially life-threatening illness caused by the protozoan parasite Trypanosoma cruzi. Chagas disease is considered a neglected tropical disease. It is endemic in 21 countries in the Americas, although the migration of infected people can transport the disease to non-endemic countries of America and the world.

The rise in the number of Chagas disease cases will be the driving factor of the market in this region. For instance, according to the Pan American Health Organization, It is estimated that, in the Americas, Chagas disease shows an annual incidence of 30,000 new cases on average, 12,000 deaths per year, and approximately 9,000 newborns become infected during gestation. It is estimated that around 70 million people in the Americas live in exposure areas and are at risk of contracting this disease.

Moreover, in this region, key players' strategies such as partnerships and collaboration, well-established healthcare infrastructure, and major players' focus on research and developments would propel this market growth. For instance, in June 2022, The Pan American Health Organization (PAHO) and Unitaid launched a five-year, US$ 2.6 million partnership to scale up regional and national efforts to eliminate mother-to-child transmission of Chagas disease.

Also, in September 2022, Researchers from the University of Georgia discovered a potential treatment for Chagas disease, marking the first medication with a promise to successfully and safely target the parasitic infection in over 50 years. Human clinical trials of the drug, an antiparasitic compound known as AN15368, will hopefully begin in the next few years.

Market Segmentation

By Type

• Acute Chagas Disease
• Chronic Chagas Disease

By Drugs

• Benznidazole
• Nifurtimox
• Others

By Route of administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • The Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the Chagas disease market include Bayer AG, Novartis AG, Laboratorio Elea Phoenix, Maprimed, Nortec Quimica SA, Upsher-Smith Laboratories, Inc., Merck and Co., ChemFish Tokyo Co., Ltd., Anant Pharmaceuticals Pvt. Ltd., and InBios International Inc.

Key Developments

• In February 2024, The Healthy Brazil program was announced in partnership with the World Health Organization (WHO). The federal government launched a public policy to try to eliminate, as a public health problem, or reduce the incidence of 14 diseases that mainly affect populations in situations of social vulnerability, such as malaria, Chagas disease, HIV, and tuberculosis.
• In January 2024, a DNDi clinical trial for the treatment of Chagas disease carried out in Spain with a mostly Latin American population showed that the drug fexinidazole was well tolerated by patients in low doses, although it was not effective in the sustained elimination of the parasite Trypanosoma cruzi, which causes the disease.
• In April 2023, Kephera Diagnostics announced World Chagas Day, that it will be launching testing for Chagas disease through its CLIA-certified. Kephera will offer two tests - an FDA-approved ELISA and a new, multiplex test for Chagas disease - both of which detect antibodies to the parasitic agent that causes the disease.

Why Purchase the Report?

• To visualize the global Chagas disease market segmentation based on type, drugs, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of global Chagas disease market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The global Chagas disease market report would provide approximately 70 tables, 61 figures, and 183 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Drugs
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Prevalence of Chagas Disease
    • 4.1.1.2. Government Initiatives & Growing Awareness about the Disease
    • 4.1.1.3. Availability of Funding for Research and Development of New Drugs
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of the Treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. DMI Opinion

6. By Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Acute Chagas Disease *
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Chronic Chagas Disease

7. By Drugs

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 7.1.2. Market Attractiveness Index, By Drugs
• 7.2. Benznidazole *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Nifurtimox
• 7.4. Others

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Oral*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Parenteral

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Online Pharmacies
• 9.4. Retail Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of administration
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of administration
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. UK
    • 10.3.7.3. France
    • 10.3.7.4. Italy
    • 10.3.7.5. Russia
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of administration
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of administration
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of administration
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Bayer AG*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Novartis AG
• 12.3. Laboratorio Elea Phoenix
• 12.4. Maprimed
• 12.5. Nortec Quimica SA
• 12.6. Upsher-Smith Laboratories, Inc
• 12.7. Merck and Co
• 12.8. ChemFish Tokyo Co., Ltd
• 12.9. Anant Pharmaceuticals Pvt. Ltd
• 12.10. InBios International Inc

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us